This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing Current Treatments for Eosinophilic Esophagitis (EoE) and the Potential of EP-104GI from Eupraxia Pharmaceuticals

Ticker(s): EPRX, SNY, TAK, AZN, GSK, MRK

Who's the expert?

Institution: McGill

  • Associate Professor of Medicine in the Division of Gastroenterology 
  • Current McGill University Division Director for Gastroenterology and Hepatology
  • Strong interest in IBD and EoE and has published over 100 peer-reviewed articles in the field

Interview Questions
Q1.

How many EoE patients do you manage?

Added By: wilson_admin
Q2.

How are EoE patients currently being managed?

Added By: wilson_admin
Q3.

Where would EP-104GI fit into your treatment algorithm?

Added By: wilson_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.